Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan
NCT01598051
·
clinicaltrials.gov ↗
COMPLETED
Status
741
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-valvular Atrial Fibrillation (NVAF)
Interventions
DRUG:
Rivaroxaban (Xarelto_ BAY59-7939)
Sponsor
Bayer
Collaborators
[object Object]